Table 4.
Multivariate analysis results of outcomes of ato-oxy for OSA treatment in children with Down syndrome.
| Baseline | Low Dose | High Dose | P | |||
|---|---|---|---|---|---|---|
| Low vs Baseline | High vs Baseline | Low vs High | ||||
| Obstructive AHI | 7.4 ± 3.7 | 3.6 ± 3.3 | 3.9 ± 2.8 | <.001 | <.001 | .31 |
| Arousal index | 15 ± 6 | 17 ± 8 | 15 ± 10 | .99 | .80 | .54 |
| N1 sleep (%) | 3 ± 4 | 4 ± 3 | 4 ± 3 | .16 | .16 | .93 |
| N3 sleep (%) | 33 ± 14 | 29 ± 9 | 33 ± 10 | .21 | .49 | .23 |
| REM sleep (%) | 14 ± 5 | 12 ± 8 | 13 ± 10 | .67 | .62 | .94 |
| OSA-18 total score | 52 ± 18 | 44 ± 17 | 47 ± 16 | .76 | .96 | .53 |
| PedsQL total score | 64 ± 16 | 68 ± 15 | 67 ± 14 | .83 | .92 | .76 |
Data is presented as mean ± standard deviation. OSA-18: OSA-specific health-related quality of life, lower scores indicate better quality of life. PedsQL: General pediatric health-related quality of life, higher scores indicate better quality of life. P values derived from linear mixed effects model after adjusting for period and dose sequence effects. AHI = apnea-hypopnea index, ato-oxy = atomoxetine and oxybutynin, OSA = obstructive sleep apnea, PedsQL = Pediatric Quality of Life inventory, REM = rapid eye movement.